Monday, November 9, 2026
Supernus Pharmaceuticals receives bullish analyst coverage initiation
An analyst started covering Supernus Pharmaceuticals with a positive view. The initiation was among several analyst coverage starts noted for Monday.
JP Morgan starts Iambic Therapeutics coverage with Overweight rating and $22 price target
JP Morgan began covering Iambic Therapeutics with an Overweight rating and set a $22 price target. The rating reflects the bank's positive view on the stock.
Citigroup starts Iambic Therapeutics coverage with Buy rating and $22 price target
Citigroup began covering Iambic Therapeutics and rated the shares Buy. The firm set a $22 price target on the stock.
B of A Securities starts Iambic Therapeutics coverage with Buy rating and $30 price target
B of A Securities began covering Iambic Therapeutics with a Buy rating. The firm set a price target of $30.
Monday, October 26, 2026
Iambic Therapeutics reports new IAM1363 data at ESMO Congress 2026
The company gave an update on its IAM1363 inhibitor, sharing clinical findings at the ESMO Congress 2026. The presentation covers results from the drug's ongoing study.
Frequently asked questions
What is the latest news on IAM?
Nov 9, 2026: Supernus Pharmaceuticals receives bullish analyst coverage initiation (Benzinga) · Nov 9, 2026: JP Morgan starts Iambic Therapeutics coverage with Overweight rating and $22 price target (Benzinga) · Nov 9, 2026: Citigroup starts Iambic Therapeutics coverage with Buy rating and $22 price target (Benzinga)
Get IAM news as it happens
Every headline, SEC filing and analyst action for IAM on your live chart, with important news marked and alerts when it matters.
Try SEPT Free